High-dose chemotherapy and allogeneic immunotherapy

[1]  A. Ballestrero,et al.  Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer , 2005, The Lancet.

[2]  B. Horisberger,et al.  Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey , 2004, Bone Marrow Transplantation.

[3]  M. Piccart,et al.  Facts and controversies in systemic treatment of metastatic breast cancer. , 2004, The oncologist.

[4]  S. Steinberg,et al.  Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Childs,et al.  Nonmyeloablative allogeneic immunotherapy for solid tumors. , 2004, Annual review of medicine.

[6]  R. Storb,et al.  Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. , 2003, Blood.

[7]  E. Warren,et al.  The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. , 2003, Blood reviews.

[8]  R. Storb,et al.  Hematopoietic cell transplantation for benign hematological disorders and solid tumors. , 2003, Hematology. American Society of Hematology. Education Program.

[9]  C. Voena,et al.  Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. , 2002, Blood.

[10]  P. Richardson,et al.  Status of high-dose chemotherapy for breast cancer: a review. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  S. Martino,et al.  Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. , 2000, The New England journal of medicine.

[12]  G. Hortobagyi,et al.  Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Marth,et al.  Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. , 1996, Blood.